Background: Neuromyelitis optica (NMO) is a disorder distinct from multiple sclerosis, and is characterized by the presence of anti-aquaporin4 (AQP4) antibody. Rituximab (RTX), which is a monoclonal antibody against CD-20, is recommended as immunotherapy in guidelines, however, the rationale is based on the results of observational or single-arm studies.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect